{"id":"94337f24-16d7-563d-960b-87104bb898e0","stable_key":"52871722-4aa6-5453-a902-3e76356db327:resveratrol-human-cyp2c9","predicate":"decreased_phenotypic_activity","statement":"After 1 g/day resveratrol for four weeks, the healthy-volunteer study found decreased CYP2C9 phenotypic activity using losartan as the probe.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"048e6553-f146-5700-9840-cf6067725edc","mechanism_event_label":"A human drug-metabolism interaction was measured with a specific probe.","subject":{"id":"53549e32-e6b4-5f09-94e6-62867b015713","slug":"resveratrol","display_name":"Resveratrol","entity_type_key":"small_molecule"},"object":{"id":"c96f78f4-5bca-5867-9ac1-652891d40aa0","slug":"cyp2c9","display_name":"Human cytochrome P450 2C9","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"048e6553-f146-5700-9840-cf6067725edc","stable_key":"52871722-4aa6-5453-a902-3e76356db327:resveratrol-human-cyp2c9-event","event_type":"observed_relationship","label":"A human drug-metabolism interaction was measured with a specific probe.","description":"After 1 g/day resveratrol for four weeks, the healthy-volunteer study found decreased CYP2C9 phenotypic activity using losartan as the probe.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"53549e32-e6b4-5f09-94e6-62867b015713","slug":"resveratrol","display_name":"Resveratrol","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"c96f78f4-5bca-5867-9ac1-652891d40aa0","slug":"cyp2c9","display_name":"Human cytochrome P450 2C9","entity_type_key":"protein"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"7d9a24e8-27b3-55c5-8cce-4c245004582e","slug":"losartan","display_name":"Losartan","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"42 initiated; enzyme activities assessed in 40; before/after pharmacological-dose study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Probe indices are not proof of transcriptional induction or a quantified interaction with every substrate; no medication adjustment follows.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Resveratrol collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"resveratrol","display_name":"Resveratrol","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"A human drug-metabolism interaction was measured with a specific probe.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20716633/ · DOI 10.1158/1940-6207.CAPR-09-0155","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"53a08eea-2de2-5b07-bb88-b0f8961208af","evidence_kind":"source_excerpt","locator":"Lines 430-436","start_line":430,"end_line":436,"excerpt":"## resveratrol-human-cyp2c9\nA human drug-metabolism interaction was measured with a specific probe.\nAfter 1 g/day resveratrol for four weeks, the healthy-volunteer study found decreased CYP2C9 phenotypic activity using losartan as the probe.\nModel: 42 initiated; enzyme activities assessed in 40; before/after pharmacological-dose study.\nLimitations: Probe indices are not proof of transcriptional induction or a quantified interaction with every substrate; no medication adjustment follows.\nEvidence access: Primary full text\nResveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20716633/ · DOI 10.1158/1940-6207.CAPR-09-0155","model_system":"42 initiated; enzyme activities assessed in 40; before/after pharmacological-dose study.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2844eda9-a122-5357-ae47-cd58227c5994","stable_key":"import-52871722-4aa6-5453-a902-3e76356db327","title":"Resveratrol: metabolites, target selectivity and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"04885b4bee72f912a7f3f618f1b2bf79c944dbcb20500398c2729fc8228dcd9a","revision_id":"99504ff2-f1d3-5f4c-bc31-e1030d27a918","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}